Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Lower-risk myelodysplastic syndromes, drawn from the whole corpus: 9 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No approved treatment for thrombocytopenia or neutropenia in lower-risk disease.
Whether early disease-modifying treatment changes the natural history rather than the transfusion count.
Iron overload management and quality of life are under-studied.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 16 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
More patients achieved transfusion independence with a haemoglobin rise on luspatercept than on epoetin alfa; first-line approval in August 2023.
Imetelstat produced eight-week transfusion independence in significantly more patients than placebo; approved in June 2024.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.